Current Business Affairs Global Cancer Biomarkers Market 2018

Cancer Biomarkers Market - Global Industry Analysis, Size, Share,
Growth, Trends, and Forecast To 2025
Market Definition:
The global cancer biomarkers market size was valued at USD 10.27 Billion in 2016 and is expected to reach USD 26.80
Billion in 2025, growing at a CAGR of over 11.35% over the forecast period. Increasing demand for cancer detection
techniques and requirement of high-speed noninvasive diagnosis using genomics and proteomics are a few drivers of
this market.
A biological molecule that can be found in blood, other body fluids or tissues indicating the normalcy or abnormality of
any biological process, or of a disease/condition etc. is called a biomarker. Cancer biomarkers are molecules, substances
or processes that can indicate the presence of cancers in body. Biomarkers are either secreted by the cancer tissues
themselves or are produced as a response to cancer by other cells in the body. They are present in urine, blood, tumor
tissue, stool, other tissues or bodily fluids. Myriad of pharmaceutical and biotech companies employ biomarkers during
their drug discovery and developmental process. This helps company’s strategic alliances for sharing technology for
biomarker applications during large-stage clinical trials which is fueling the growth of this market.
Get PDF with Technological trends at https://www.xpodenceresearch.com/Request-Sample/106916
Market Analysis with Latest Growth Factors:
On the basis of cancer type, the cancer biomarker is classified into breast, multiple myeloma, melanoma, thyroid, liver,
prostate, lung, leukemia, colorectal, central nervous system (CNS), bladder, gastric, kidney, and other cancers, such as
cervical, non-Hodgkin’s lymphoma, pharynx, pancreatic, oral cavity, stomach and ovarian cancers.
Breast cancer is anticipated to account for the maximum share in the global cancer biomarkers market. Increased focus
of key companies on developing novel diagnostic assays is an essential driver for the growth of this market. Globally,
numerous initiatives are being organized in order to increase the awareness of breast cancer ensuring early detection of
the condition, thereby adding to the number of diagnostic scans. This factor is anticipated to drive market growth in this
segment.
Major Key Players:
Some of the major players in the cancer biomarkers market are Merck, Abbott, Agilent, Roche, Hologic, Illumina , Becton
Dickinson, Affymetrix, Thermo Fisher, and QIAGEN.